

**Cilostazol (Pletal<sup>®</sup>)**

**No. 86/04**

**Otsuka Pharmaceutical Europe**

## **Summary of Recommendation**

8 February, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Cilostazol (Pletal<sup>®</sup>) is not recommended within NHS Scotland for the treatment of intermittent claudication.

It improves maximal and pain-free-walking distances more than placebo, but has limited effects on quality of life assessments. There are concerns about clinical effectiveness, including potential for several major drug interactions including with antiplatelet therapy which is recommended by the Scottish Intercollegiate Guidelines Network (SIGN) for patients with peripheral vascular disease. The economic case for this product has not been proven and it is substantially more expensive than its competitors.

Professor David H Lawson  
Chairman